CymaBay Therapeutics Announces Positive Results from its Pilot Phase 2 Clinical Study of MBX-8025 in Patients with Homozygous Familial Hypercholesterolemia
March 17, 2016 16:01 ET
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., March 17, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY) today announced top line results from its pilot Phase 2 clinical study of MBX-8025 in patients with...